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2009-2010 Influenza Season 
Week 12 ending March 27, 2010 
All data are preliminary and may change as more reports are received. 
 
Synopsis: During week 12 (March 21-27, 2010), influenza activity remained at approximately the 
same level as last week in the U.S. 
o 97 (3.5%) specimens tested by U.S. World Health Organization (WHO) and National 
Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories and 
reported to CDC/Influenza Division were positive for influenza. 
o Approximately 98% of all subtyped influenza A viruses reported to CDC were 2009 influenza 
A (H1N1) viruses. 
o The proportion of deaths attributed to pneumonia and influenza (P&I) was slightly above the 
epidemic threshold.  
o One influenza-associated pediatric death was reported and was associated with 2009 
influenza A (H1N1) virus infection. 
o The proportion of outpatient visits for influenza-like illness (ILI) was 1.6%, which is below the 
national baseline of 2.3%.  One of 10 regions (Region 9) reported ILI above its region-
specific baseline. 
o No states reported widespread influenza activity.  Three states reported regional influenza 
activity.  Puerto Rico and seven states reported local influenza activity.  The District of 
Columbia, Guam and 30 states reported sporadic influenza activity.  Ten states reported no 
influenza activity, and the U.S. Virgin Islands did not report. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative since August 30, 2009 (Week 35)* 
HHS 
Surveillance 
Regions** 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
A (H1) A (H3) 2009 A (H1N1) 
A  
(unable 
to sub-
type)¥ 
A 
(Subty-
ping not 
perfor-
med) 
B  Pediatric Deaths 
Nation Normal 3.5% 3 of 54 35 65 66,589 289 22,320 287 269 
Region 1 Normal  0.6% 0 of 6 4 4 3,402 14 503 11 6 
Region 2 Normal 1.0% 0 of 4 8 6 1,797 0 2,394 12 19 
Region 3 Normal 2.1% 0 of 6 3 11 10,697 48 1,453 18 14 
Region 4 Normal 13.8% 3 of 8 1 8 9,950 95 4,645 87 51 
Region 5 Normal 2.6% 0 of 6 8 25 9,479 47 1,577 19 36 
Region 6 Normal 6.0% 0 of 5 2 3 5,137 19 5,372 54 71 
Region 7 Normal 6.2% 0 of 4 3 1 3,261 3 849 9 8 
Region 8 Normal 1.4% 0 of 6 4 2 9,851 0 3,936 56 16 
Region 9 Elevated 0.9% 0 of 5 0 4 8,335 49 1,244 18 38 
Region 10 Normal 0.5% 0 of 4 2 1 4,680 14 347 3 10 
*Influenza season officially begins each year at week 40. This season data from week 35 will be included to show the trend of influenza activity before the official start of the 
2009-10 influenza season. 
**HHS regions (Region 1 CT, ME, MA, NH, RI, VT; Region 2: NJ, NY, Puerto Rico, US Virgin Islands; Region 3: DE, DC, MD, PA, VA, WV; Region 4: AL, FL, GA, KY, MS, NC, 
SC, TN; Region 5: IL, IN, MI, MN, OH, WI; Region 6: AR, LA, NM, OK, TX; Region 7: IA, KS, MO, NE; Region 8: CO, MT, ND, SD, UT, WY; Region 9: AZ, CA, Guam, HI, NV; 
and Region 10: AK, ID, OR, WA).  Use of the national baseline for regional data or regional baselines for state data is not appropriate. 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline. 
‡ National data are for current week; regional data are for the most recent three weeks. 
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and U.S. Virgin Islands. 
¥ Subtyping results for the majority of specimens in this category were inconclusive because of low virus titers. 
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U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories, located in all 50 
states and Washington, D.C., report to CDC the number of respiratory specimens tested for 
influenza and the number positive by influenza type and subtype. The results of tests performed 
during the current week are summarized in the table below. 
 Week 12 
No. of specimens tested 2,775 
No. of positive specimens (%) 97 (3.5%) 
Positive specimens by type/subtype  
Influenza A 97 (100.0%) 
          A (2009 H1N1)   59 (60.8%)  
          A (subtyping not performed)          37 (38.1%)
          A (unable to subtype)  0 (0.0%)  
          A (H3)                1 (1.0%)  
          A (H1) 0 (0.0%)
Influenza B 0 (0.0%) 
 
During week 12, no influenza B viruses and one influenza A (H3N2) virus were reported, the 
remaining 59 (98.3%) subtyped influenza A viruses reported to CDC this week were 2009 influenza 
A (H1N1) viruses. 
 
Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS Collaborating 
Laboratories, National Summary, August 30, 2009-March 27, 2010 
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Pneumonia and Influenza Hospitalization and Death Tracking: The Aggregate Hospitalization 
and Death Reporting Activity (AHDRA) system was implemented on August 30, 2009, and replaces 
the weekly report of laboratory confirmed 2009 H1N1-related hospitalizations and deaths that 
began in April 2009.  Jurisdictions report to CDC the number of hospitalizations and deaths 
resulting from all types or subtypes of influenza, not just those associated with 2009 H1N1.  Counts 
were reset to zero on August 30, 2009.  From August 30, 2009 – March 27, 2010, 41,689 
laboratory-confirmed influenza-associated hospitalizations and 2,096 laboratory-confirmed 
influenza-associated deaths were reported to CDC.  
Weekly Laboratory-Confirmed Influenza-Associated Hospitalizations and 
Deaths Reported to AHDRA,  
National Summary, August 30, 2009 – March 27, 2010 
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Antigenic Characterization: CDC has antigenically characterized two seasonal influenza A 
(H1N1), 13 influenza A (H3N2), 23 influenza B, and 1,609 2009 influenza A (H1N1) viruses 
collected since September 1, 2009.  
Both seasonal influenza A (H1N1) viruses tested were related to the influenza A (H1N1) 
component of the 2009-10 Northern Hemisphere influenza vaccine (A/Brisbane/59/2007).  
The 13 influenza A (H3N2) viruses tested showed reduced titers with antisera produced against 
A/Brisbane/10/2007, the 2009-2010 Northern Hemisphere influenza A (H3N2) vaccine component, 
and were antigenically related to A/Perth/16/2009, the WHO recommended influenza A (H3N2) 
component of the 2010 Southern Hemisphere and 2010-11 Northern Hemisphere vaccine 
formulations. 
Influenza B viruses currently circulating globally can be divided into two distinct lineages 
represented by the B/Yamagata/16/88 and B/Victoria/02/87 viruses.  The influenza B component 
of the 2009-10 and 2010-11 Northern Hemisphere vaccines belongs to the B/Victoria lineage.  The 
23 influenza B viruses tested belong to the B/Victoria lineage and are related to the influenza 
vaccine component for the 2009-10 and 2010-11 Northern Hemisphere influenza B vaccine strain 
(B/Brisbane/60/2008).    
One thousand six hundred four (99.7%) of 1,609 2009 influenza A (H1N1) viruses tested are related 
to the A/California/07/2009 (H1N1) reference virus selected by WHO as the 2009 H1N1 vaccine 
virus, and as a component in the 2010-11 Northern Hemisphere vaccine.  Five viruses (0.3%) 
tested showed reduced titers with antiserum produced against A/California/07/2009.  
Annual influenza vaccination is expected to provide the best protection against those virus strains 
that are related to the vaccine strains, but limited to no protection may be expected when the 
vaccine and circulating virus strains are so different as to be from different lineages.  Antigenic 
characterization of 2009 influenza A (H1N1) viruses indicates that these viruses are only distantly 
related antigenically and genetically to seasonal influenza A (H1N1) viruses, suggesting that little to 
no protection would be expected from vaccination with seasonal influenza vaccine.   
Composition of the 2010-11 Influenza Vaccine:  WHO has recommended vaccine strains for the 
2010-11 Northern Hemisphere trivalent influenza vaccine, and FDA has made the same 
recommendations for the U.S. influenza vaccine.  Both agencies recommend that the vaccine 
contain A/California/7/2009-like (2009 H1N1), A/Perth/16/2009-like (H3N2), and 
B/Brisbane/60/2008-like (B/Victoria lineage) viruses.  A seasonal influenza A (H1N1) component is 
not included in the 2010-11 formulation, and the A (H3N2) component has been changed from the 
2009-10 Northern Hemisphere vaccine formulation.  This recommendation was based on 
surveillance data related to epidemiology and antigenic characteristics, serological responses to 
2009-10 trivalent seasonal and 2009 H1N1 monovalent vaccines, and the availability of candidate 
strains and reagents. 
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Antiviral Resistance: Since September 1, 2009, one seasonal influenza A (H1N1), 13 influenza A 
(H3N2), 23 influenza B, and 1,617 2009 influenza A (H1N1) virus isolates have been tested for 
resistance to the neuraminidase inhibitors (oseltamivir and zanamivir), and 2,672 2009 influenza A 
(H1N1) original clinical samples were tested for a single known mutation in the virus that confers 
oseltamivir resistance.  In addition, one seasonal influenza A (H1N1), 13 influenza A (H3N2), and 
1,608 2009 influenza A (H1N1) virus isolates have been tested for resistance to the adamantanes 
(amantadine and rimantadine).  The results of antiviral resistance testing performed on these 
viruses are summarized in the table below. Additional laboratories perform antiviral testing and 
report their results to CDC, and positive results from that testing are included in the footnote. 
Antiviral Resistance Testing Results on Samples Collected Since September 1, 2009. 
 Viruses tested (n) 
Resistant 
Viruses, 
Number (%) 
Viruses 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Isolates 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Oseltamivir Zanamivir Adamantanes 
Seasonal 
Influenza A 
(H1N1) 
1 1 (100.0) 0 0 (0) 1 0 (0) 
Influenza A 
(H3N2) 13 0 (0) 0 0 (0) 13 13 (100.0) 
Influenza B 23 0 (0) 0 0 (0) N/A* N/A* 
2009 
Influenza A  
(H1N1) 
4,289 52†‡ (1.2) 1,617 0 (0) 1,608 1,604 (99.8) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
†Two screening tools were used to determine oseltamivir resistance: sequence analysis of viral genes and a neuraminidase inhibition assay. 
‡ Additional laboratories perform antiviral resistance testing and report their results to CDC.  Three additional oseltamivir resistant 2009 influenza 
A (H1N1) virus has been identified by these laboratories since September 1, 2009, bringing the total number to 55. 
 
Approximately 98% of all subtyped influenza A viruses reported during week 12 were 2009 
influenza A (H1N1) viruses, and nearly all of 2009 H1N1 viruses tested since April 2009 have been 
resistant to the adamantanes (amantadine and rimantadine).   
 
Antiviral treatment with oseltamivir or zanamivir is recommended for all patients with confirmed or 
suspected influenza virus infection who are hospitalized, are at higher risk for influenza 
complications, or who have lower respiratory tract or progressive disease.  Additional information on 
antiviral recommendations for treatment and chemoprophylaxis of influenza virus infection is 
available at http://www.cdc.gov/H1N1flu/recommendations.htm.   
 
2009 influenza A (H1N1) viruses were tested for oseltamivir resistance by a neuraminidase 
inhibition assay and/or detection of genetic sequence mutation, depending on the type of specimen 
tested.  Original clinical samples were examined for a single known mutation in the virus that 
confers oseltamivir resistance in currently circulating seasonal influenza A (H1N1) viruses, while 
influenza virus isolates were tested using a neuraminidase inhibition assay that determines the 
presence or absence of neuraminidase inhibitor resistance, followed by neuraminidase gene 
sequence analysis of resistant viruses.   
 
The majority of 2009 influenza A (H1N1) viruses are susceptible to the neuraminidase inhibitor 
antiviral medication oseltamivir; however, rare sporadic cases of oseltamivir resistant 2009 
influenza A (H1N1) viruses have been detected worldwide.  A total of 64 cases of oseltamivir 
resistant 2009 influenza A (H1N1) viruses have been identified in the United States since April 
2009. This total includes two newly identified cases since last week.  Fifty-five of these specimens 
were collected after September 1, 2009.  The proportion of oseltamivir-resistant 2009 H1N1 viruses 
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does not represent the prevalence of oseltamivir-resistant 2009 H1N1 in the United States.  Most 
cases were tested because drug resistance was suspected.  All tested viruses retained their 
sensitivity to the neuraminidase inhibitor zanamivir.  Of the 64 total cases identified since April 
2009, 52 patients had documented exposure to oseltamivir through either treatment or 
chemoprophylaxis, eight patients are under investigation to determine exposure to 
oseltamivir, three patients had no documented oseltamivir exposure, and in one patient, exposure 
cannot be determined.  Occasional development of oseltamivir resistance during treatment or 
prophylaxis is not unexpected.  Enhanced surveillance, an increased availability of testing 
performed at CDC, and an increasing number of public health and other clinical laboratories 
performing antiviral resistance testing increase the number of cases of oseltamivir resistant 2009 
influenza A (H1N1) viruses detected.  All cases are investigated to assess the spread of resistant 
strains in the community.     
 
To prevent the spread of antiviral resistant virus strains, CDC reminds clinicians and the public of 
the need to continue hand and cough hygiene measures for the duration of any symptoms of 
influenza, even while taking antiviral medications 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5832a3.htm).  
 
 
Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 12, 7.9% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage was 
slightly above the epidemic threshold of 7.8% for week 12.  
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending 3/27/2010 
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Influenza-Associated Pediatric Mortality:  One influenza-associated pediatric death was reported 
to CDC during week 12 (New York City) and was associated with 2009 influenza A (H1N1) virus 
infection.  This death occurred during week 9 (the week ending March 6, 2010). 
 
Since August 30, 2009, CDC has received 269 reports of influenza-associated pediatric deaths that 
occurred during the current influenza season (48 deaths in children less than 2 years old, 30 deaths 
in children 2-4 years old, 100 deaths in children 5-11 years old, and 91 deaths in children 12-17 
years old).  Two hundred nineteen (81%) of the 269 deaths were due to 2009 influenza A (H1N1) 
virus infections, 49 were associated with an influenza A virus for which the subtype is 
undetermined, and one was associated with an influenza B virus infection.  A total of 279 deaths in 
children associated with 2009 influenza A (H1N1) virus infection have been reported to CDC. 
 
Among the 269 deaths in children, 144 children had specimens collected for bacterial culture from 
normally sterile sites and 49 (34.0%) of the 144 were positive; Streptococcus pneumoniae was 
identified in 11 (22.4%) of the 49 children, and Staphylococcus aureus was identified in 14 (28.6%) 
of the 49 children.  Four S. aureus isolates were sensitive to methicillin, nine were methicillin 
resistant, and one did not have sensitivity testing performed.  Thirty-two (65.3%) of the 49 children 
with bacterial coinfections were five years of age or older, and 17 (34.7%) of the 49 children were 
12 years of age or older. 
 
Laboratory-Confirmed Influenza-Associated Pediatric Deaths by Date and 
Type/Subtype of Influenza. 
Date 2009 H1N1 Influenza 
Influenza A- 
Subtype 
Unknown 
Seasonal 
Influenza Total 
Number of Deaths REPORTED 
for Current Week – Week 12 
(Week ending March 27, 2010) 
1 0 0 1 
Number of Deaths OCCURRED 
since August 30, 2009 219 49 1 269 
Number of Deaths OCCURRED 
since April 26, 2009 279 52 2 333 
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Number of Influenza-Associated Pediatric Deaths by Week of Death: 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored using a population-based surveillance network that includes the 10 
Emerging Infections Program (EIP) sites (CA, CO, CT, GA, MD, MN, NM, NY, OR and TN) and 6 
new sites (IA, ID, MI, ND, OK and SD). 
During September 1, 2009 – March 27, 2010, the following preliminary laboratory-confirmed overall 
influenza associated hospitalization rates were reported by EIP and the new sites (rates include 
influenza A, influenza B, and 2009 influenza A (H1N1)): 
Rates [EIP (new sites)] for children aged 0-4 years and 5-17 years were 6.6 (10.5) and 2.5 (3.6) per 
10,000, respectively. Rates [EIP (new sites)] for adults aged 18-49 years, 50-64 years, and ≥ 65 
years were 2.4 (1.7), 3.2 (2.0) and 2.7 (1.8) per 10,000, respectively. 
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EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates, 
2009-10 and Previous Three Seasons* 
18161412108642525048464442403836
Week
2009-10 Network case count 2009-10 New sites rate
2009-10 EIP rate 2008-09 EIP rate*
2007-08 EIP rate 2006-07 EIP rate
10.0
8.0
6.0
4.0
2.0
0.0
65+ yr
18-49 yr
5-17 yr
0-4 yr
50-64 yr
Cu
mu
lat
ive
 R
ate
 p
er
 10
,00
0 P
op
ula
tio
n
Case   Count
10.0
8.0
6.0
4.0
2.0
0.0
10.0
8.0
6.0
4.0
2.0
0.0
10.0
8.0
6.0
4.0
2.0
0.0
10.0
8.0
6.0
4.0
2.0
0.0
400
300
200
100
0
400
300
200
100
0
400
300
200
100
0
400
300
200
100
0
400
300
200
100
0
 
 
* The 2008-09 EIP rate ended as of April 14, 2009 due to the onset of the 2009 H1N1 season. 
 
2009-2010 Influenza Season – Week 12, ending March 27, 2010           
 
10
 
Outpatient Illness Surveillance: Nationwide during week 12, 1.6% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is below the national baseline of 2.3%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
Weekly National Summary, October 1, 2006 – March 27, 2010 
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.4% to 3.3% during 
week 12.  One of the 10 regions (Region 9) reported ILI above its region-specific baseline.  (Note: 
Use of the national baseline for regional ILI data or regional baselines for state-level data is not 
appropriate.) 
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 Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and 2009 influenza A (H1N1) viruses and does not measure the severity of 
influenza activity. 
 
During week 12, the following influenza activity was reported: 
 No states reported widespread influenza activity. 
 Regional influenza activity was reported by three states (Alabama, Georgia, and South 
Carolina). 
 Local influenza activity was reported by Puerto Rico and seven states (Arkansas, Hawaii, 
Louisiana, Maine, North Carolina, Tennessee, and Virginia). 
 Sporadic influenza activity was reported by the District of Columbia, Guam, and 30 states 
(Alaska, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa, Kansas, 
Kentucky, Maryland, Michigan, Minnesota, Mississippi, Missouri, Nevada, New Jersey, New 
Mexico, New York, Ohio, Oklahoma, Pennsylvania, South Dakota, Texas, Vermont, 
Washington, West Virginia, Wisconsin, and Wyoming). 
 Ten states (Delaware, Idaho, Massachusetts, Montana, Nebraska, New Hampshire, North 
Dakota, Oregon, Rhode Island, and Utah) reported no influenza activity. 
 The U.S. Virgin Islands did not report. 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
  Report prepared: April 2, 2010. 
 
